BNGO Clinical research

Bionano Announces Publication Showing Utility of Optical Genome Mapping in Clinical Research of Infant & Toddler T-ALL

Published August 07, 2025 at 12:00 PM

SAN DIEGO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced a peer-reviewed publication from a team led by Manon Delafoy from the Institut Necker Enfants Malades (INEM) and colleagues from multiple French pediatric hematology centers showing how optical genome mapping (OGM) can be used to detect oncogenic structural variants (SVs) in clinical research of infant and toddler T-cell acute lymphoblastic leukemia (T-ALL). The publication shows that OGM can reveal distinct genetic drivers and prognostic subgroups that conventional cytogenetics failed to identify in a retrospective, national cohort of 27 T-ALL cases of infants and toddlers (<3 years) as part of a combined workflow of targeted sequencing, OGM, and RNA sequencing. Infants and toddlers can be a difficult segment of the population to analyze because their cancers are rare. The study conclusions support using OGM as a complementary tool to conventional assays to help accurately stratify sam

Related Questions

How will the announcement of this OGM study affect Bionano's stock price in the short- and medium‑term? Are there existing or pending partnerships with hospitals, diagnostic labs, or pharmaceutical companies that could leverage this research? How does the reported utility of OGM compare to competing genomic technologies (e.g., NGS, long‑read sequencing, other optical mapping platforms) in terms of sensitivity, turnaround time, and cost? Will the publication accelerate adoption of Bionano’s platform in clinical labs, and if so, how quickly could that translate into measurable sales? What is the size of the addressable market for OGM in pediatric leukemia, and how much of it can Bionano realistically capture? What are the revenue implications of using OGM as a complementary tool in the pediatric oncology market? Will the results impact Bionano’s current guidance or lead to an update of its earnings forecasts? How might this publication influence future funding, collaborations, or grant opportunities for Bionano? Does the study suggest a regulatory pathway (e.g., FDA clearance or CE marking) that could unlock reimbursement or broader clinical use? What are the competitive implications for other companies offering structural‑variant detection (e.g., Illumina, PacBio, Oxford Nanopore, 10x Genomics, and other optical mapping firms)? How could this publication affect Bionano’s intellectual‑property position or lead to new patents? What risks or limitations were identified in the study that could affect commercial adoption (e.g., sample requirements, turnaround time, data analysis complexity)?